Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921141 | 0.80 | CYP17A1 (0.37) | — | |
| SCHEMBL18921160 | 0.72 | SLC22A12 (0.43) | CA2PTGS1PTGS2SLC22A12CA1 | |
| SCHEMBL29948921 | 0.71 | CA2 (0.41) | CA2PTGS1PTGS2SLC22A12CA1 | |
| SCHEMBL26674802 | 0.71 | CA2 (0.36) | CA2CA1KMT2A | |
| SCHEMBL6658979 | 0.70 | CA2 (0.67) | CA2PTGS1PTGS2SLC22A12CA1 | |
| SCHEMBL26674684 | 0.70 | MAPT (0.34) | MEN1KMT2A | |
| SCHEMBL21598422 | 0.70 | GAA (0.35) | HTTKMT2A | |
| SCHEMBL2489790 | 0.68 | PTGS1 (0.45) | CA2PTGS1PTGS2SLC22A12CA1 | |
| SCHEMBL21597026 | 0.67 | L3MBTL1 (0.39) | CA2CA1MEN1KMT2A | |
| SCHEMBL30641199 | 0.67 | LATS1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363656-A1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3383868-B1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3383868-A1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095724-A1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363656-A1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | LTB4R2, LTB4R, LTC4S | CA2 3594/4885PTGS1 78/4885PTGS2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.